Drugs / MERCAPTOPURINE ANHYDROUS
last change 3 days ago re-read 2 minutes ago

MERCAPTOPURINE ANHYDROUS

Small molecule targets HPRT1, PPAT via inhibition

Developed for
leukemia · acute lymphoblastic leukemia · lymphoblastic lymphoma · childhood acute lymphoblastic leukemia · Crohn disease · lymphoma · adult acute lymphoblastic leukemia · B-cell acute lymphoblastic leukemia
+28 more · acute promyelocytic leukemia · ulcerative colitis · B-cell childhood acute lymphoblastic leukemia · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · glioblastoma · inflammatory bowel disease · Langerhans cell histiocytosis · lymphoid leukemia · precursor B-cell acute lymphoblastic leukemia · precursor lymphoblastic lymphoma/leukemia · acute leukemia · acute leukemia of ambiguous lineage · acute myeloid leukemia · acute myeloid leukemia, t(15;17)(q24;q21) · anaplastic astrocytoma · anaplastic oligodendroglioma · B-lymphoblastic leukemia/lymphoma with hypodiploidy · breast cancer · colitis · intestinal obstruction · metastatic malignant neoplasm · mixed glioma · mixed phenotype acute leukemia · myelodysplastic/myeloproliferative neoplasm · ovarian cancer · primary brain neoplasm · T-cell acute lymphoblastic leukemia · myelodysplastic syndrome
Investigated by
National Cancer Institute (NCI) · Children's Oncology Group · PETHEMA Foundation · M.D. Anderson Cancer Center · St. Jude Children's Research Hospital · Goethe University
+94 more · SWOG Cancer Research Network · Dana-Farber Cancer Institute · GIMEMA Foundation · Institute of Hematology & Blood Diseases Hospital, China · Alliance for Clinical Trials in Oncology · Chonnam National University Hospital · Deutsche Krebshilfe e.V., Bonn (Germany) · Johann Wolfgang Goethe University Hospital · Massachusetts General Hospital · Pusan National University Yangsan Hospital · Qilu Hospital of Shandong University · Rigshospitalet, Denmark · Seoul National University Hospital · Seoul St. Mary's Hospital · Severance Hospital · Shanghai Children's Medical Center · Teva GTC · AbbVie · Asan Medical Center · Australasian Gastro Intestinal Research Foundation · Beth Israel Deaconess Medical Center · Boston Children's Hospital · Children's Cancer Group, China · Children's Cancer and Leukaemia Group · Children's Hospital of Hebei Province · Children's Hospital of Philadelphia · Children's Hospital of Soochow University · DRC lille, France · Danish Cancer Society · Dutch Childhood Oncology Group · Emory University · Enzon Pharmaceuticals, Inc. · EsPhALL · European Acute Promyelocytic Leukemia Group · European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma · European Organisation for Research and Treatment of Cancer - EORTC · European Working Group of MDS in Childhood · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Genzyme, a Sanofi Company · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa · Hee Young Ju · Histiocyte Society · Ho Joon Im · Indiana University · Italian Association of Pediatric Hematology and Oncology · Jazz Pharmaceuticals · Jeju National University Hospital · Kjeld Schmiegelow · Korea University Anam Hospital · Kristoffer Rohrberg · Martin Schrappe · Medical Research Council · Memorial Sloan Kettering Cancer Center · Mylan Pharmaceuticals Inc · NCIC Clinical Trials Group · Nanjing Children's Hospital · National Institute of Allergy and Infectious Diseases (NIAID) · National Institutes of Health Clinical Center (CC) · National University Hospital, Singapore · National University of Singapore · Nordic Society for Pediatric Hematology and Oncology · North American Consortium for Histiocytosis · Prince of Wales Hospital, Shatin, Hong Kong · Prof. Arie Levine · Qianfoshan Hospital · Radboud University Medical Center · Rush University Medical Center · Saint-Louis Hospital, Paris, France · Samsung Medical Center · Shandong University · Shanxi Bethune Hospital · St Vincent's Hospital Melbourne · Sun Yat-sen University · all 100 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Xaluprine (previously Mercaptopurine Nova Laboratories) 2012-03-09 europa.eu
Approved US (FDA) PURINETHOL 1953-09-11 fda.gov

Trials 103 · started per year

today
US approved 1953
EU approved 2012
1
4
3
5
3
3
5
7
1
2
4
4
2
2
6
5
3
2
1
2
2
1
8
4
3
4
1
1
3
1
4
1
5
195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05506332 Jul 2022 → Dec 2024 overdue acute myeloid leukemia University Hospital, Antwerp Recruiting No outcome recorded
Phase 1 NCT00774982 Dec 2008 → Feb 2009 Crohn disease Teva GTC Completed No outcome recorded
Phase 1 NCT00648336 Nov → Dec 2003 Mylan Pharmaceuticals Inc Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT05276284 Sep 2022 → Dec 2024 metastatic malignant neoplasm Kristoffer Rohrberg Completed No outcome recorded
Phase 1/2 NCT06279767 Jul 2022 → Jul 2025 glioblastoma The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
Phase 1/2 NCT00287170 Jul 2006 → Dec 2007 Crohn disease Teva GTC Completed No outcome recorded
Phase 233 trials
Phase 2 NCT07643103 Jun 2026 → May 2028 expected precursor B-cell acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT07227584 Apr 2026 → Jul 2030 expected acute lymphoblastic leukemia Dana-Farber Cancer Institute Not yet recruiting No outcome recorded
Phase 2 NCT05827549 Apr 2024 → Dec 2032 expected acute lymphoblastic leukemia Ho Joon Im Recruiting No outcome recorded
Phase 2 NCT06387121 Apr 2024 → Dec 2026 expected precursor lymphoblastic lymphoma/leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2 NCT06099366 Mar 2024 → Dec 2033 expected childhood acute lymphoblastic leukemia Hee Young Ju Recruiting No outcome recorded
Phase 2 NCT04845035 Jan 2024 → Jan 2026 acute lymphoblastic leukemia University of Michigan Rogel Cancer Center Withdrawn No outcome recorded
Phase 2 NCT05645718 Jul 2023 → Dec 2027 expected leukemia M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2 NCT03518112 Apr 2018 → May 2021 B-cell acute lymphoblastic leukemia M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 2 NCT03488225 Mar 2018 → Apr 2020 B-cell acute lymphoblastic leukemia M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 2 NCT02877303 Nov 2016 → Nov 2026 expected B-cell acute lymphoblastic leukemia, lymphoblastic lymphoma M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT07059156 Jun 2025 → Jun 2027 expected adult acute lymphoblastic leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2/3 NCT04228393 Feb 2020 → Dec 2022 childhood acute lymphoblastic leukemia Wei Zhao Unknown No outcome recorded
Phase 2/3 NCT02205762 Nov 2016 → Jul 2026 overdue Langerhans cell histiocytosis North American Consortium for Histiocytosis Active not recruiting No outcome recorded
Phase 331 trials
Phase 3 NCT03643276 Jul 2018 → Jul 2028 expected childhood acute lymphoblastic leukemia Martin Schrappe Recruiting No outcome recorded
Phase 3 NCT04773366 Jul 2018 → Jun 2023 Langerhans cell histiocytosis Shanghai Children's Medical Center Unknown No outcome recorded
Phase 3 NCT03007147 Aug 2017 → Sep 2027 expected B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia Children's Oncology Group Active not recruiting No outcome recorded
Phase 3 NCT02845882 Jan 2016 → Dec 2023 overdue lymphoblastic lymphoma Children's Cancer Group, China Active not recruiting No outcome recorded
Phase 3 NCT01503632 Feb 2012 → Jun 2019 acute lymphoblastic leukemia Children's Oncology Group Completed No outcome recorded
Phase 3 NCT01190930 Aug 2010 → Mar 2019 B-cell childhood acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma with hypodiploidy, B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), Down syndrome +1 Children's Oncology Group Completed No outcome recorded
Phase 3 NCT00866918 Mar 2009 → Jun 2015 acute promyelocytic leukemia Children's Oncology Group Completed No outcome recorded
Phase 3 NCT00816049 Jan 2009 → Mar 2016 acute lymphoblastic leukemia Rigshospitalet, Denmark Completed No outcome recorded
Phase 3 NCT00707083 May 2008 → Oct 2018 leukemia Prince of Wales Hospital, Shatin, Hong Kong Completed No outcome recorded
Phase 3 NCT00492856 Jun 2007 → Dec 2013 leukemia SWOG Cancer Research Network Completed No outcome recorded
Phase 418 trials
Phase 4 NCT07248644 May → Sep 2026 expected ulcerative colitis Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa Not yet recruiting No outcome recorded
Phase 4 NCT03220841 Oct 2017 → Sep 2020 Crohn disease, intestinal obstruction St Vincent's Hospital Melbourne Unknown No outcome recorded
Phase 4 NCT04304950 Apr 2016 → Dec 2021 inflammatory bowel disease Rush University Medical Center Completed No outcome recorded
Phase 4 NCT02177071 Oct 2015 → Jun 2021 Crohn disease Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives Completed No outcome recorded
Phase 4 NCT03920813 Jan 2015 → Dec 2021 acute lymphoblastic leukemia Shandong University Unknown No outcome recorded
Phase 4 NCT01906671 Jun 2013 → Sep 2018 acute lymphoblastic leukemia Kjeld Schmiegelow Unknown No outcome recorded
Phase 4 NCT01802593 Feb 2013 → Dec 2015 Crohn disease Prof. Arie Levine Terminated No outcome recorded
Phase 4 NCT02894645 Oct 2008 → Oct 2018 childhood acute lymphoblastic leukemia National University Hospital, Singapore Unknown No outcome recorded
Phase 4 NCT02036489 Jan 2008 → Dec 2019 acute lymphoblastic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00199017 Apr 2004 → Mar 2009 lymphoblastic lymphoma Johann Wolfgang Goethe University Hospital Completed No outcome recorded
Phase not applicable12 trials
NCT07443592 Mar 2026 → Mar 2031 expected acute lymphoblastic leukemia PETHEMA Foundation Not yet recruiting No outcome recorded
NCT07462299 Feb 2026 → Jan 2028 expected childhood acute lymphoblastic leukemia The Children's Hospital of Zhejiang University School of Medicine Not yet recruiting No outcome recorded
NCT04179929 Nov 2019 → Nov 2026 expected acute lymphoblastic leukemia PETHEMA Foundation Recruiting No outcome recorded
NCT03370601 Jan 2017 → Jan 2019 inflammatory bowel disease University Hospital, Lille Terminated No outcome recorded
NCT03390387 Nov 2015 → Nov 2020 childhood acute lymphoblastic leukemia Federal Research Institute of Pediatric Hematology, Oncology and Immunology Unknown No outcome recorded
NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
NCT02413047 May 2015 → Feb 2018 Crohn disease, ulcerative colitis Indiana University Terminated No outcome recorded
NCT01156883 Apr 2010 → Oct 2017 leukemia GIMEMA Foundation Completed No outcome recorded
NCT00521950 Sep 2007 → Dec 2011 Crohn disease, ulcerative colitis ZonMw: The Netherlands Organisation for Health Research and Development Completed No outcome recorded
NCT00096135 Nov 2004 → Sep 2013 leukemia Children's Oncology Group Completed No outcome recorded
Also used as a comparator or background therapy in 120 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT05157971 Background Mar 2022 → Apr 2027 expected B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like City of Hope Medical Center Active not recruiting No outcome recorded
Phase 1 NCT03571321 Background May 2019 → Sep 2026 expected childhood acute lymphoblastic leukemia University of Chicago Recruiting No outcome recorded
Phase 1 NCT02303821 Background Feb 2015 → Jun 2024 acute lymphoblastic leukemia Amgen Completed No outcome recorded
Phase 1 NCT02228772 Background Dec 2014 → Oct 2016 B-cell adult acute lymphocytic leukemia, T-cell adult acute lymphocytic leukemia, lymphoblastic lymphoma Massachusetts General Hospital Completed No outcome recorded
Phase 1 NCT00866307 Background Feb 2009 → Jun 2014 B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia Children's Oncology Group Completed No outcome recorded
Phase 1/210 trials
Phase 1/2 NCT06199557 Comparator May 2024 → Nov 2025 overdue acute myeloid leukemia, myelodysplastic syndrome Haukeland University Hospital Recruiting No outcome recorded
Phase 1/2 NCT05848687 Background Nov 2023 → Dec 2028 expected acute lymphoblastic leukemia Tanja Andrea Gruber Recruiting No outcome recorded
Phase 1/2 NCT05192889 Background Aug 2022 → Jun 2024 overdue acute lymphoblastic leukemia St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 1/2 NCT05032183 Background Feb 2022 → Jul 2024 B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 1/2 NCT03319901 Background Oct 2017 → Nov 2025 overdue leukemia Dana-Farber Cancer Institute Active not recruiting No outcome recorded
Phase 242 trials
Phase 2 NCT07636564 Background Oct 2026 → Apr 2031 expected B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage SWOG Cancer Research Network Not yet recruiting No outcome recorded
Phase 2 NCT06918431 Background Oct 2025 → Mar 2029 expected B-cell acute lymphoblastic leukemia, lymphoblastic lymphoma City of Hope Medical Center Recruiting No outcome recorded
Phase 2 NCT06317662 Background Jun 2025 → Dec 2028 expected B-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT06124157 Background May 2025 → Dec 2030 expected B-cell acute lymphoblastic leukemia National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT06533748 Background Jan 2025 → May 2028 expected lymphoblastic lymphoma, precursor B-cell acute lymphoblastic leukemia St. Jude Children's Research Hospital Recruiting No outcome recorded
Phase 2/38 trials
Phase 2/3 NCT07072585 Background Aug 2026 → Sep 2035 expected T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma Children's Oncology Group Not yet recruiting No outcome recorded
Phase 2/3 NCT03117751 Background Mar 2017 → Sep 2026 expected lymphoblastic leukemia, acute, with lymphomatous features St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT03553238 Background Feb 2016 → May 2020 T lymphoblastic leukemia/lymphoma, T-cell leukemia, acute leukemia Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT03564704 Background Feb 2016 → May 2021 T-cell leukemia, adult acute lymphoblastic leukemia, lymphoblastic lymphoma Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 2/3 NCT02532738 Background Jan 2016 → Nov 2018 Crohn disease Sixth Affiliated Hospital, Sun Yat-sen University Unknown No outcome recorded
Phase 341 trials
Phase 3 NCT05681260 Background Feb 2023 → Dec 2026 expected T-lymphoblastic lymphoma Children's Cancer Group, China Recruiting No outcome recorded
Phase 3 NCT06059989 Background Nov 2021 → Jun 2025 overdue Crohn disease, inflammatory disease Academic Medical Center - University of Amsterdam Recruiting No outcome recorded
Phase 3 NCT03959085 Background Oct 2019 → Mar 2032 expected B-cell acute lymphoblastic leukemia, central nervous system leukemia, lymphoblastic lymphoma, mixed phenotype acute leukemia +1 Children's Oncology Group Recruiting No outcome recorded
Phase 3 NCT04043494 Background Aug 2019 → Apr 2030 expected lymphoblastic lymphoma University Hospital Muenster Recruiting No outcome recorded
Phase 3 NCT03914625 Background Jul 2019 → Sep 2027 expected B-cell acute lymphoblastic leukemia, Down syndrome, lymphoblastic lymphoma National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 46 trials
Phase 4 NCT02852694 Comparator Feb 2017 → Jun 2021 Crohn disease PIBD-Net Completed No outcome recorded
Phase 4 NCT02200978 Background Sep 2011 → Oct 2021 acute promyelocytic leukemia South China Children's Leukemia Group Completed No outcome recorded
Phase 4 NCT01358253 Background Dec 2010 → Dec 2012 adult acute lymphoblastic leukemia Ruijin Hospital Completed No outcome recorded
Phase 4 NCT00846703 Comparator Jul 2008 → Dec 2013 acute lymphoblastic leukemia Sun Yat-sen University Unknown No outcome recorded
Phase 4 NCT00199004 Background Apr 2004 → Mar 2009 adult acute lymphoblastic leukemia Johann Wolfgang Goethe University Hospital Completed No outcome recorded
Phase not applicable7 trials
NCT07454226 Background May 2026 → Mar 2028 expected acute lymphoblastic leukemia, phosphohydroxylysinuria Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
NCT07495631 Background Apr 2026 → Mar 2028 expected adult acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
NCT07431060 Background Feb 2026 → Dec 2030 expected multisystem langerhans cell histiocytosis West China Second University Hospital Recruiting No outcome recorded
NCT06639958 Background Dec 2024 → Mar 2027 childhood acute lymphoblastic leukemia Children's Oncology Group Suspended No outcome recorded
NCT00550992 Background Jan 2006 → Dec 2020 leukemia Dutch Childhood Oncology Group Unknown No outcome recorded
Phase not stated1 trial
NCT01085617 Background Dec 2010 → Feb 2025 leukemia, mouth disorder, mucositis University College, London Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2003-07-01 Teva Branded Pharmaceutical Products R&D, Inc. Teva Receives North American Rights to Purinethol® as Part of Glaxosmithkline Settlement tevapharm.com

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 230 sources stand behind the page.

FieldValueCited text
Known as MERCAPTOPURINE ANHYDROUS ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as 6-mercaptopurine “The delayed-release test drugs are 6-mercaptopurine (at a dose of 40 mg daily) or calcitriol (at a dose of 5 mcg three times a week) versus Purinethol (6-MP at a dose of 1-2...” NCT00287170
62

“continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, oral-ly), according to a 2-by-2 factorial design stratified on the initial induction...” NCT00599937

“Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered” NCT00816049

“Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine” NCT03319901

“Includes vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, and high-dose methotrexate.” NCT07495631

“The longest treatment phase in both protocols is maintenance therapy, which is composed of 6-Mercaptopurine (6MP) and Methotrexate (MTX).” NCT02912676

“Maintenance therapy with dose-reduced POMP (6-mercaptopurine, vincristine, methotrexate, and prednisone) was given for 3 years.” PMID 37187201 May 2023

“We aimed to compare the rates of POR in patients treated early with prophylactic 6-mercaptopurine (6-MP) or adalimumab.” PMID 38137669 Dec 2023

“Patients randomized to IFX combination therapy will also receive 6-mercaptopurine 1-1.5 mg/kg.” NCT06059989

6-Mercaptopurine by mouth daily NOTE: Only high risk patients will receive 6-Mercaptopurine” NCT02670707

“Initial dosage of 6-Mercaptopurine (6-MP) is stratified based on NUDT15 and TPMT genotypes:” NCT07462299

“Drug:6-mercaptopurine 60 mg/m2/d,po,d1-d28,during maintenance treatment for 2 years” NCT02042690

“a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home” NCT06639958

6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39” NCT02451774

“The IBD medications being observed are azathioprine and 6-mercaptopurine.” NCT04304950

“Allopurinol is added to standard oral 6-mercaptopurine and methotrexate” NCT03022747

“Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally.” NCT00482833

“a continuous regimen of methotrexate and 6-mercaptopurine.” NCT00700544

6-mercaptopurine (60 mg/m2/day, per os, days 43-71)” NCT03390387

“6MP (6-mercaptopurine) 75 mg/m2 PO daily x 7 days” NCT00187005

“Oral 6-mercaptopurine 50 mg/m2/day PO (days 1-14)” NCT05827549

“formulation of 6-mercaptopurine (Xaluprine)” NCT01906671

“azathioprine (AZA)/6-mercaptopurine (6MP)” PMID 32611737 Jul 2020

6-Mercaptopurine 25 mg/m2 per day, d1-56” NCT02845882

“6- Mercaptopurine 60 mg/m2 po qd” NCT01429610

“Purinethol (6-Mercaptopurine)” NCT04747912

“Drug: 6-MP (6-Mercaptopurine)” NCT01920737

6-mercaptopurineNCT07248644

NCT00199056

NCT03384654

NCT01432145

NCT03286634

NCT05681260

NCT00521950

NCT02413047

NCT00774982

NCT05276284

NCT02894645

NCT03564704

NCT06387121

NCT06199557

NCT00548431

NCT06533748

NCT01094613

NCT02852694

NCT00973752

NCT02303821

NCT01358253

NCT04043494

NCT02660762

NCT00199069

NCT05660473

NCT06279767

NCT00184041

NCT00846703

NCT02518750

NCT05506332

NCT04228393

NCT03553238

NCT00176462

NCT00514982

NCT02845882

NCT03643276

Known as 6-mercaptopurine (6-MP) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00136435
Known as 6-mercaptopurine monohydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as 6MP “Immunosuppressives, e.g. azathioprine (AZA) and 6-mercaptopurine (6-MP), are important in induction of remission and long term treatment of (ulcerative) colitis and Crohn's...” NCT00521950
28

“Efficacy and myelosuppression of azathioprine/6-mercaptopurine (AZA/6-MP) are correlated with the metabolite 6-thioguanine, while the metabolite 6-methylmercaptopurine...” PMID 36730289 Feb 2023

“The delayed-release test drugs are 6-mercaptopurine (at a dose of 40 mg daily) or calcitriol (at a dose of 5 mcg three times a week) versus Purinethol (6-MP at a dose of 1-2...” NCT00287170

“The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP...” NCT01094613

“Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.” NCT07454226

6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.” NCT01629628

“The longest treatment phase in both protocols is maintenance therapy, which is composed of 6-Mercaptopurine (6MP) and Methotrexate (MTX).” NCT02912676

“Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks” NCT01802593

“6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.” NCT06279767

“Initial dosage of 6-Mercaptopurine (6-MP) is stratified based on NUDT15 and TPMT genotypes:” NCT07462299

“Mercaptopurine (6MP) is essential to cure childhood acute lymphoblastic leukemia (ALL).” PMID 32519032 Jun 2020

“a medicine called 6-mercaptopurine or "6MP" is taken by mouth every day at home” NCT06639958

“Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally.” NCT00482833

“the new delayed release, lowered dose, 40 mg 6MP test formulation” NCT00774982

“1. 6-mercaptopurine (6MP) 50 mg/m2 orally taken once a day,” NCT05276284

“The Drug including 6MP, AZA, infliximab and thalidomide” NCT02532738

“6-mercaptopurine (6-MP) on days 36 to 63 (28 days)” NCT01117441

6MP (6-mercaptopurine) 75 mg/m2 PO daily x 7 days” NCT00187005

“6-MP: 50-75 mg/m²/day fasting (7-14 days PO).” NCT07059156

“azathioprine (AZA)/6-mercaptopurine (6MP)” PMID 32611737 Jul 2020

“IDR + CY + ARA-C + ASP + 6MP + DXM + IT” NCT02067143

“basic daily 6MP (6-mercaptopurine)” NCT00548431

“6-MP 75 mg/m2 PO; daily x 7” NCT00187057

“6-Mercaptopurine (6-MP)” NCT06199557

“Mercaptopurine (6-MP)” NCT02910245

NCT00962767

NCT01920737

NCT00476190

NCT02200978

Known as Mercaptopurina ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as mercaptopurine “with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin,...” NCT04845035
158

“The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP...” NCT01094613

“plus thiopurine (initial dose of azathioprine 2·5 mg/kg or mercaptopurine 1·5 mg/kg, with dose adjustment based on thiopurine metabolite testing)” PMID 34890567 Dec 2021

Mercaptopurine (6MP) is essential to cure childhood acute lymphoblastic leukemia (ALL).” PMID 32519032 Jun 2020

“Maintenance (Methotrexate, Mercaptopurine).” NCT07443592

“Maintenance (Methotrexate, Mercaptopurine)” NCT04179929

Mercaptopurine: 60 mg/m2 po on days 35-59” NCT02396043

“Melphalan Mercaptopurine Methotrexate” NCT02551718

NCT02688140

NCT00047268

NCT00002665

NCT00707083

NCT01230983

NCT00003423

NCT04546399

NCT01228331

NCT07227584

NCT03007147

NCT02523976

NCT00262925

NCT00059839

NCT00853008

NCT00002618

NCT00458848

NCT06336395

NCT01503632

NCT00003934

NCT02881086

NCT00720109

NCT00764907

NCT00131027

NCT00526175

NCT02877303

NCT00492856

NCT02419755

NCT00002514

NCT00494897

NCT00186875

NCT00003671

NCT05192889

NCT00430118

NCT03488225

NCT00276601

NCT06099366

NCT00343369

NCT02910245

NCT01256398

NCT02419469

NCT03914625

NCT02177071

NCT00061945

NCT00131053

NCT00558519

NCT00866307

NCT00199095

NCT00526305

NCT02003222

NCT01156883

NCT00136084

NCT07072585

NCT03920813

NCT00003700

NCT00551460

NCT00002700

NCT00866749

NCT02723994

NCT00381680

NCT00671034

NCT00003650

NCT00482833

NCT00103285

NCT02828358

NCT00096135

NCT07431060

NCT07643103

NCT06210750

NCT00002812

NCT00003437

NCT05157971

NCT02143414

NCT00002701

NCT00005945

NCT02776605

NCT00187005

NCT02883049

NCT00187057

NCT01085617

NCT02553460

NCT04216524

NCT00003783

NCT02228772

NCT00022737

NCT03370601

NCT00400946

NCT03150693

NCT00866918

NCT03571321

NCT00002704

NCT00187083

NCT04440267

NCT00187122

NCT03117751

NCT00003728

NCT01371630

NCT06124157

NCT01117441

NCT00018954

NCT00002531

NCT00549848

NCT02420717

NCT07636564

NCT00199017

NCT01700946

NCT05303792

NCT00002785

NCT00089349

NCT00005585

NCT01190930

NCT00005603

NCT00004228

NCT06639958

NCT00199004

NCT02112916

NCT05848687

NCT06317662

NCT00109837

NCT05032183

NCT00019409

NCT00408005

NCT03518112

NCT00004688

NCT00557193

NCT00137111

NCT06390319

NCT06918431

NCT00648336

NCT02205762

NCT02101853

NCT02036489

NCT05645718

NCT00022126

NCT00016302

NCT00002766

NCT04773366

NCT00075725

NCT03020030

NCT00198991

NCT01451515

NCT01005758

NCT00275106

NCT00501826

NCT00198978

NCT00613457

NCT00002756

NCT00002744

NCT00550992

NCT00005596

NCT03959085

NCT00015873

Known as Mercaptopurine hydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as Mercaptopurinum ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as NSC-755 ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as NSC-759614 ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as Puri-Nethol (6-mercaptopurine) “PuriNethol, Puri-Nethol (6-mercaptopurine)NCT00816049
Known as PuriNethol “Maintenance therapy with dose-reduced POMP (purinethol [6-mercaptopurine], oncovin [vincristine sulfate], methotrexate, and prednisone) was given for 3 years.” PMID 29352703 Jan 2018
4

“Pharmacokinetics of 50 mg 6MP tablet (Puri-Nethol®) and 20 mg/ml 6MP liquid suspension (Xaluprine®) were compared” PMID 32519032 Jun 2020

PuriNethol, Puri-Nethol (6-mercaptopurine)” NCT00816049

“standard 6MP (100 mg Purinethol)” NCT00774982

NCT04747912

Known as Purixan ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Known as Xaluprine “Pharmacokinetics of 50 mg 6MP tablet (Puri-Nethol®) and 20 mg/ml 6MP liquid suspension (Xaluprine®) were compared” PMID 32519032 Jun 2020
Known as Xaluprine (previously mercaptopurine nova laboratories) ChEMBL registry synonym — accepted as the source's own label CHEMBL1425
Action Inhibit “6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity” NCT06279767
1

“Amidophosphoribosyltransferase inhibitor” CHEMBL1425

Modality Other / unclassified “Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia.” NCT00514982
Route Oral oral mercaptopurine (MP) once daily” NCT00002514
Target HPRT1 “6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity” NCT06279767
Target PPAT “Amidophosphoribosyltransferase inhibitor” CHEMBL1425